explore -WSS

explore

author：fashion 2025-09-29 12:30:17 - browse：1897

illustration of a colorful DNA strand, partly broken into pieces. -- health coverage from STAT — Adobe

BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning.

In the study, run by Excision BioTherapeutics, researchers tried to use the gene editing tool to address a chief reason HIV has been so hard to cure. While antiviral drugs can clear patients of replicating virus, HIV is able to worm its way into a patients’ own DNA in certain cells. If the patient ever stops taking medicines, those cells start pumping out HIV particles and the infection roars back.

Researchers hoped they could send CRISPR to those cells and, by cutting the HIV DNA lurking there at two spots, slice out the virus. In the Phase 1 trial, investigators administered the treatment to five patients. They then took three of them off conventional antiviral treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Emergent cuts jobs, executive role in business shake

knowledge

WSS

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

Maui's cultural, historic landmarks damaged in the devastating wildfires

10 reasons why health care startups fail

Investment in vaccine development is lagging, report finds

Zyn nicotine pouches become unlikely player in latest culture war

Anavex keeps shifting the goalposts in its clinical trials

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

In Memoriam: Notable people who died in 2023

Wegovy leads to weight loss. Can it treat depression, too?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Man killed during FBI raid in connection with threats against Biden, other officials

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

In Memoriam: Notable people who died in 2023

Medicare drug price negotiation legal challenge met with skepticism

Guidelines to prevent youth baseball injuries need more muscle

Philips to halt sales of sleep apnea machines in U.S.

focus

South Korea throws huge K

Emergent cuts jobs, executive role in business shake

Pancreatic cancer early detection could be helped by AI

Why failed clinical trials don’t always spell doom for a new drug

The best solution to the drug shortages problem

Why you shouldn’t ask, “What country has the best health care?”

explore

leisure time

knowledge

Wikipedia